MX339452B - Tableta con nucleo recubierto de liberacion controlada. - Google Patents

Tableta con nucleo recubierto de liberacion controlada.

Info

Publication number
MX339452B
MX339452B MX2012014437A MX2012014437A MX339452B MX 339452 B MX339452 B MX 339452B MX 2012014437 A MX2012014437 A MX 2012014437A MX 2012014437 A MX2012014437 A MX 2012014437A MX 339452 B MX339452 B MX 339452B
Authority
MX
Mexico
Prior art keywords
controlled release
nucleated tablet
isobutyloxyphenyl
cyano
methyl
Prior art date
Application number
MX2012014437A
Other languages
English (en)
Other versions
MX2012014437A (es
Inventor
Kentaro Fujinaga
Susumu Maruo
Hideaki Nakamura
Kenji Sunagawa
Tsutomu Mochizuki
Michiharu Kageyama
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2012014437A publication Critical patent/MX2012014437A/es
Publication of MX339452B publication Critical patent/MX339452B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una tableta de liberación controlada que contiene un núcleo interno y una porción de capa externa que cubre el núcleo interno, la cual puede mantener la concentración de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-ti azolcarboxílico en la sangre a un cierto nivel o superior durante un largo período de tiempo, donde el núcleo interno contiene ácido 2-(3-ciano-4-isobutiloxifenhl)-4-metil-5-tiazolcarboxílico, y la porción de capa externa contiene ácido 2-(3-ciano-4-isobutilo xifenil)-4-metil-5-tiazol carboxílico y un polímero hidrosoluble formador de gel en una cantidad de 16%. (p/p) o superior con respecto al peso de la porción de capa externa.
MX2012014437A 2010-06-16 2011-06-15 Tableta con nucleo recubierto de liberacion controlada. MX339452B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010137322 2010-06-16
JP2010137323 2010-06-16
PCT/JP2011/063713 WO2011158870A1 (ja) 2010-06-16 2011-06-15 放出制御型の有核錠剤

Publications (2)

Publication Number Publication Date
MX2012014437A MX2012014437A (es) 2013-02-26
MX339452B true MX339452B (es) 2016-05-27

Family

ID=45348267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014437A MX339452B (es) 2010-06-16 2011-06-15 Tableta con nucleo recubierto de liberacion controlada.

Country Status (9)

Country Link
US (1) US8968779B2 (es)
EP (1) EP2594269A4 (es)
JP (1) JP5669837B2 (es)
AR (1) AR081935A1 (es)
CA (1) CA2802831C (es)
MX (1) MX339452B (es)
TW (1) TW201206502A (es)
UY (1) UY33455A (es)
WO (1) WO2011158870A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579037A (zh) 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
CN111511353A (zh) 2017-06-21 2020-08-07 田边三菱制药株式会社 耐胃液的控释口服剂型
JP7377782B2 (ja) * 2019-09-04 2023-11-10 信越化学工業株式会社 フィルム成形用組成物及びフィルム
JP7506475B2 (ja) * 2019-12-26 2024-06-26 東和薬品株式会社 フェブキソスタット製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ATE307803T1 (de) 1999-01-22 2005-11-15 Boehringer Ingelheim Pharma Herstellung von 3-amino-2-chlor-4-methylpyridin aus aceton und ethylcyanoacetat
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4637338B2 (ja) 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP4817562B2 (ja) * 2001-09-26 2011-11-16 東和薬品株式会社 長時間持続型ニフエジピン有核錠
JP5105684B2 (ja) 2002-03-15 2012-12-26 大塚製薬株式会社 持続性医薬製剤
JP3751287B2 (ja) 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
ES2505690T3 (es) * 2002-03-28 2014-10-10 Teijin Pharma Limited Preparación sólida que contiene una forma única de cristal de un derivado de ácido tiazolcarboxílico
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1915989A4 (en) * 2005-08-18 2012-05-30 Teijin Pharma Ltd PREPARATION WITH DIVISION FUNCTION IN ACCURATE DOSES
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
ZA200805646B (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
CA2632962A1 (en) 2006-01-10 2007-07-19 Yasuhiro Takeda Sustained release preparation and method for production thereof
CA2687192C (en) * 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20100221335A1 (en) 2007-08-31 2010-09-02 Daiichi Sankyo Company, Limited Sustained-release preparation and method for producing the same
JP5351490B2 (ja) * 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
KR20120096920A (ko) * 2009-06-26 2012-08-31 데이진 화-마 가부시키가이샤 고혈압증 또는 정상 고치 혈압증의 치료약
CN101671315B (zh) * 2009-08-19 2011-06-22 何广卫 非布索坦的新晶型及其制备方法
CN101658505A (zh) * 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
AU2011268445B2 (en) * 2010-06-16 2015-05-07 Takeda Pharmaceuticals U.S.A., Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Also Published As

Publication number Publication date
US20130089609A1 (en) 2013-04-11
CA2802831C (en) 2018-11-20
AR081935A1 (es) 2012-10-31
CA2802831A1 (en) 2011-12-22
EP2594269A1 (en) 2013-05-22
EP2594269A4 (en) 2013-12-04
JPWO2011158870A1 (ja) 2013-08-19
UY33455A (es) 2012-01-31
TW201206502A (en) 2012-02-16
MX2012014437A (es) 2013-02-26
JP5669837B2 (ja) 2015-02-18
US8968779B2 (en) 2015-03-03
WO2011158870A1 (ja) 2011-12-22

Similar Documents

Publication Publication Date Title
IL253737A0 (en) Systems and methods for extracorporeal treatment of an organ and for the use of lactate as a sign of donor organ status
IL264441A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
BR112013010078A2 (pt) sistema de prevenção de ferida de pressão e método para evitar o desenvolvimento de feridas de pressão de um indivíduo
WO2012040248A3 (en) Automatic association of medical elements
BR112012030561A2 (pt) sistema dealívio de tensão de implante de glossoplastia, método para indicar uma quanidade de força aplicada pela língua de um indivíduo a um sistema implantável e sistema implantável configurado para indicar uma quantidade de força aplicada pela língua de um indivíduo ao sistema implantável
EP2480914A4 (en) Systems and methods for the quantitative estimate of production-forecast uncertainty
EP2533825A4 (en) Cannula lined with tissue in-growth material and method of using the same
HK1219055A1 (zh) 輔酶 的靜脈內製劑及其使用方法
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
IL221043A0 (en) Modified release formulation and methods of use
EP2563358A4 (en) INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1)
EP2619194A4 (en) CATECHIN FATTY ACID DERIVATIVES AND METHODS OF USE
MX2013007237A (es) Peliculas y composiciones que comprenden las mismas.
MX339452B (es) Tableta con nucleo recubierto de liberacion controlada.
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
CA2837895C (en) Methods of treating or preventing neurological diseases
PH12016501756A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
NZ702191A (en) Nalmefene for reduction of alcohol consumption in specific target populations
IN2014DN07040A (es)
PT2384623E (pt) Composição em pó para a prevenção e tratamento de doenças dos cascos de animais
WO2011163539A3 (en) nAChRα7 AGONISTS AND nAChRα7 ANTAGONISTS FOR TREATING ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD)
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
WO2009013885A1 (ja) Ｔ細胞のＴｈ１細胞への分化抑制剤
HU1000229D0 (en) Equipment for registering the excitement level as well as determining and recording the excitement condition of human beings
ZA201209294B (en) Association of xanthine oxidase inhibitors and statins and use thereof

Legal Events

Date Code Title Description
FG Grant or registration